Proviral Integration of Moloney Virus-2 (PIM-2) Expression Level as a Prognostic Marker in Patients with Acute Myeloid Leukemia

References

• Patel J, Gonen M, Figueroa M, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:10.1056/NEJMoa1112304
   PubMed Web of Science ®Google Scholar
• Thol F, Heuser M, Damm F, Klusmann J, Reinhardt K, Reinhardt D. DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica. 2011;96(8):1238–1240. doi:10.3324/haematol.2011.046839
   PubMed Web of Science ®Google Scholar
• Khorshid O, Diaa A, Abd El Moaty M, et al. Clinical features and treatment outcome of acute promyelocytic leukemia patients treated at Cairo National Cancer Institute in Egypt. Mediterr J Hematol Infect Dis. 2011;3(1):e2011060. doi:10.4084/mjhid.2011.060
   PubMedGoogle Scholar
• Döhner H, Weisdorf D, Bloomfield C. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra1406184
   PubMed Web of Science ®Google Scholar
• Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010;95(6):1004–1015. doi:10.3324/haematol.2009.017079
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Giles F, Swords R. The PIM kinases in hematological cancers. Expert Rev Hematol. 2012;5(1):81–96. doi:10.1586/ehm.11.69
   PubMed Web of Science ®Google Scholar
• Wernig G, Gonneville J, Crowley B, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008;111(7):3751–3759. doi:10.1182/blood-2007-07-102186
   PubMed Web of Science ®Google Scholar
• Keeton E, McEachern K, Dillman K, et al. AZD1208, a potent and selective pan-pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123(6):905–913. doi:10.1182/blood-2013-04-495366
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Taverna PM, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to pim kinase inhibitor, SGI-1776 in acute myeloid leukemia. Blood. 2011;118(3):693–702. doi:10.1182/blood-2010-12-323022
   PubMed Web of Science ®Google Scholar
• Fox C, Hammerman P, Cinalli R, Master S, Chodosh L, Thompson C. The serine/threonine kinase Pim- 2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003;17(15):1841–1854. doi:10.1101/gad.1105003
   PubMed Web of Science ®Google Scholar
• Huttmann A, Klein-Hitpass L, Thomale J, et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia. 2006;20(10):1774–1782. doi:10.1038/sj.leu.2404363
   PubMed Web of Science ®Google Scholar
• Cohen A, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45(5):951–955.
   PubMed Web of Science ®Google Scholar
• Bachmann M, Möröy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005;37(4):726–730. doi:10.1016/j.biocel.2004.11.005
   PubMed Web of Science ®Google Scholar
• Brault L, Menter T, Obermann E, et al. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer. 2012;107(3):491–500. doi:10.1038/bjc.2012.272
   PubMed Web of Science ®Google Scholar
• Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 2013;122(9):1610–1620. doi:10.1182/blood-2013-01-481457
   PubMed Web of Science ®Google Scholar
• Tamburini J, Green A, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 2009;114(8):1618–1627. doi:10.1182/blood-2008-10-184515
   PubMed Web of Science ®Google Scholar
• Kapelko-Slowik K, Owczarek T, Grzymajlo K, et al. Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia. Leuk Lymphoma. 2016;13:1–10. doi:10.3109/10428194.2015.1124991
   Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Tefferi A, Letendre L. Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia. J Clin Oncol. 2012;30(20):2425–2428. doi:10.1200/JCO.2011.38.9601
   PubMed Web of Science ®Google Scholar
• Marcucci G, Mrózek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. J Clin Oncol. 2004;22(12):2410–2418. doi:10.1200/JCO.2004.03.023
   PubMed Web of Science ®Google Scholar
• Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–1907. doi:10.1016/S0140-6736(06)69780-8
   PubMed Web of Science ®Google Scholar
• Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22(5):915–931. doi:10.1038/leu.2008.19
   PubMed Web of Science ®Google Scholar
• Conway O’Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014;2014:103175. doi:10.1155/2014/103175
   PubMedGoogle Scholar
• Mikkers H, Allen J, Knipscheer P, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002;32(1):153–159. doi:10.1038/ng950
   PubMed Web of Science ®Google Scholar
• Konietzko U, Kauselmann G, Scafidi J, et al. Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. EMBO J. 1999;18(12):3359–3369. doi:10.1093/emboj/18.12.3359
   PubMed Web of Science ®Google Scholar
• Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009;27(26):4422–4432. doi:10.1200/JCO.2008.21.3264
   PubMed Web of Science ®Google Scholar
• Hu YL, Passegué E, Fong S, Largman C, Lawrence H. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood. 2007;109(11):4732–4738. doi:10.1182/blood-2006-08-043356
   PubMed Web of Science ®Google Scholar
• El Dahshan D, Hammam A, Ahmed A, El Samra M. Expression of Proviral Integration of Moloney Virus-2 (PIM2) gene in patients with acute myeloid leukemia and its clinical significance. IJBC. 2020;12(1):6–11.
   Google Scholar
• Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101(8):3164–3173. doi:10.1182/blood-2002-06-1677
   PubMed Web of Science ®Google Scholar
• Kapelko-Słowik K, Urbaniak-Kujda D, Wołowiec D, et al. Increased expression of PIM-2 and NF-κB genes in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is associated with complete remission rate and overall survival. Postepy Hig Med Dosw. 2013;67:553–559. doi:10.5604/17322693.1052449
   Web of Science ®Google Scholar
• Abbassy H, Donia H, Ghallab O. Association of PIM2 and NF-KB with poor clinical outcome in Egyptian patients with acute myeloid leukemia. Int J Curr Res. 2016;8(07):34399–34402.
   Google Scholar
• Ren K, Zhang W, Shi Y, Gong J. pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-KB pathway. Pathol Oncol Res. 2010;16(2):229–237. doi:10.1007/s11253-009-9215-4
   PubMed Web of Science ®Google Scholar
• Li Q, Verma IM. NF-KB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725–734. doi:10.1038/nri910
   PubMed Web of Science ®Google Scholar
• Green A, Maciel T, Hospital MA, et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv. 2015;1(8):e1500221. doi:10.1126/sciadv.1500221
   PubMed Web of Science ®Google Scholar